Drug Combination Details
| General Information of the Combination (ID: C69733) | |||||
|---|---|---|---|---|---|
| Name | Silibinin NP Info | + | IPI-549 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Down-regulation | Regulatory T cells and myeloid suppressor cells | ||||
| In-vivo Model | 4T1 cells was inoculated subcutaneously into the right mammary glands of female balb/c mice. | |||||
| Experimental
Result(s) |
Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment. Int J Pharm. 2020 May 15;581:119239. | |||
